Wassim McHayleh, MD
Hematology & Oncology · Altamonte Springs, FLNPI 1093988487
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,152,996 of the $1,484,396 with a category attached, or 77.7%. It is spread thinly across 23 manufacturers, the largest accounting for just 19.2%. 2025 is the largest year on record at $392,445, 4.4 times the $88,794 reported in 2019. Among hematology & oncology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,286 payments — averaging $1154.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$285K
- AstraZeneca$270K
- Gilead$247K
- Daiichi Sankyo Inc.$163K
- Seagen Inc.$146K
- Merck$91K
- plus $282K from 17 others
Across 55 payments — averaging $35,658 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$995K
- Pfizer$375K
- Merck$307K
- AstraZeneca$219K
- Stemline Therapeutics Inc.$33K
- Genentech, Inc.$32K
- plus $1K from 1 others
What the payments were for
- Consulting fees$109,5127%
- Speaking & faculty fees$1,152,99678%
- Grants$3500%
- Travel & lodging$192,09113%
- Food & beverage$29,2792%
- Education$1680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 335 | $285,244 |
| AstraZeneca | 199 | $269,878 |
| Gilead(2 entities) | 206 | $247,364 |
| Daiichi Sankyo Inc. | 124 | $162,777 |
| Seagen Inc. | 111 | $145,848 |
| Merck | 76 | $91,380 |
| Jazz Pharmaceuticals Inc. | 83 | $79,707 |
| Stemline Therapeutics Inc. | 48 | $68,209 |
| Pfizer | 24 | $56,320 |
| E.r. Squibb & Sons, L.L.C. | 22 | $37,874 |
| Genentech USA, Inc. | 20 | $21,692 |
| Eli Lilly Export S.A. Puerto Rico Branch | 9 | $6,017 |
| Novartis | 9 | $5,946 |
| Incyte Corporation | 4 | $3,314 |
| Eli Lilly | 3 | $991 |
| Bristol Myers Squibb | 2 | $700 |
| GSK | 2 | $241 |
| Amgen | 2 | $208 |
| Tempus AI, Inc | 3 | $191 |
| Menarini Silicon Biosystems, Inc. | 1 | $137 |
| Sanofi | 1 | $129 |
| Rigel Pharmaceuticals, Inc. | 1 | $118 |
| Tersera Therapeutics LLC | 1 | $109 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,484,396 in reported general payments places this provider in the 95th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 59 | $927,548 |
| TukysaTucatinib | 35 | $596,458 |
| KisqaliRibociclib Succinate | 35 | $560,317 |
| VerzenioAbemaciclib | 34 | $507,370 |
| Lenalidomide | 32 | $429,259 |
| CabometyxCabozantinib S-Malate | 15 | $377,914 |
| PromactaEltrombopag Olamine | 13 | $336,330 |
| RevlimidLenalidomide | 19 | $327,588 |
| XtandiEnzalutamide | 12 | $169,186 |
| CalquenceAcalabrutinib Maleate | 16 | $143,131 |
| EliquisApixaban | 43 | $43,590 |
| Letrozole | 659 | $17,943 |
| XareltoRivaroxaban | 18 | $16,321 |
| Exemestane | 55 | $13,367 |
| ZarxioFilgrastim-Sndz | 14 | $11,585 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $56,320 | $971,138102 claims |
| NovartisKisqali, Promacta | $5,946 | $896,64748 claims |
| Seagen Inc.Tukysa | $145,848 | $596,45835 claims |
| Lilly USA, LLCVerzenio | $285,244 | $507,37034 claims |
| Bristol Myers SquibbRevlimid | $700 | $327,58819 claims |
| AstraZenecaCalquence | $269,878 | $143,13116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Altamonte Springs
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
- Daniel LandauOrlando$1.8M
- Edith PerezJacksonville$1.1M
- Steven FeinMiami$1M
- Vamsidhar VelchetiJacksonville$966K
- Shahram MoriOrlando$952K
- Damian LaberTampa$753K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.